8 results on '"Kurt AG"'
Search Results
2. Real-World-Erfahrungen zum Einsatz von Palbociclib am Brustzentrum des Universitätsklinikums der LMU München
- Author
-
Hester, A, additional, König, A, additional, Dobler, F, additional, Degenhardt, T, additional, Gassel, K, additional, Heidegger-Steger, H, additional, Kurt, AG, additional, Kahlert, S, additional, Mahner, S, additional, Harbeck, N, additional, and Wuerstlein, R, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study
- Author
-
Hartkopf, AD, primary, Brucker, SY, additional, Taran, F-A, additional, Harbeck, N, additional, von Au, A, additional, Naume, B, additional, Pierga, J-Y, additional, Hoffmann, O, additional, Beckmann, MW, additional, Rydén, L, additional, Fehm, T, additional, Aft, R, additional, Montserrat, S, additional, Walter, V, additional, Rack, B, additional, Schuetz, F, additional, Borgen, E, additional, Ta, M-H, additional, Bittner, A-K, additional, Fasching, P, additional, Fernö, M, additional, Krawczyk, N, additional, Weilbaecher, K, additional, Margelí, M, additional, Hahn, M, additional, Jueckstock, J, additional, Domschke, C, additional, Bidard, F-C, additional, Kasimir-Bauer, S, additional, Schoenfisch, B, additional, Kurt, AG, additional, Wallwiener, M, additional, Gebauer, G, additional, Wallwiener, D, additional, Janni, W, additional, and Pantel, K, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
- Author
-
Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, Pierga JY, Hoffmann O, Beckmann MW, Rydén L, Fehm T, Aft R, Solà M, Walter V, Rack B, Schuetz F, Borgen E, Ta MH, Bittner AK, Fasching PA, Fernö M, Krawczyk N, Weilbaecher K, Margelí M, Hahn M, Jueckstock J, Domschke C, Bidard FC, Kasimir-Bauer S, Schoenfisch B, Kurt AG, Wallwiener M, Gebauer G, Klein CA, Wallwiener D, Janni W, and Pantel K
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms mortality, Female, Humans, Middle Aged, Proportional Hazards Models, Receptor, ErbB-2 analysis, Young Adult, Bone Marrow pathology, Breast Neoplasms pathology
- Abstract
Purpose: Presence of disseminated tumour cells (DTCs) in the bone marrow (BM) has been described as a surrogate of residual disease in patients with early breast cancer (EBC). PADDY (Pooled Analysis of DTC Detection in Early Breast Cancer) is a large international analysis of pooled data that aimed to assess the prognostic impact of DTCs in patients with EBC., Experimental Design: Individual patient data were collected from 11 centres. Patients with EBC and available follow-up data in whom BM sampling was performed at the time of primary diagnosis before receiving any anticancer treatment were eligible. DTCs were identified by antibody staining against epithelial cytokeratins. Multivariate Cox regression was used to compare the survival of DTC-positive versus DTC-negative patients., Results: In total, 10,307 patients were included. Of these, 2814 (27.3%) were DTC-positive. DTC detection was associated with higher tumour grade, larger tumour size, nodal positivity, oestrogen receptor and progesterone receptor negativity, and HER2 positivity (all p < 0.001). Multivariate analyses showed that DTC detection was an independent prognostic marker for overall survival, disease-free survival and distant disease-free survival with hazard ratios (HR) and 95% confidence intervals (CI) of 1.23 (95% CI: 1.06-1.43, p = 0.006), 1.30 (95% CI: 1.12-1.52, p < 0.001) and 1.30 (95% CI: 1.08-1.56, p = 0.006), respectively. There was no association between locoregional relapse-free survival and DTC detection (HR 1.21; 95% CI 0.68-2.16; p = 0.512)., Conclusions: DTCs in the BM represent an independent prognostic marker in patients with EBC. The heterogeneous metastasis-initiating potential of DTCs is consistent with the concept of cancer dormancy., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ADH, FAT and SYB report a grant from Exact Sciences. TNF received personal fees from AstraZeneca, Novartis, Roche, Pfizer, Esai, Tesaro, Teva, Celgene, Daichi Sankyo, MSD, Menarini. PAF reports grants from Cepheid, Novartis and Biontech, personal fees from Novartis, Roche, Pfizer, Celgene, Daiichi-Sankyo, TEVA, Astra Zeneca, Merck Sharp & Dohme, Myelo Therapeutics, Macrogenics, Eisai, Puma and Lilly. CAK is a member of the SAB of HiberCell, New York. All other authors declare no potential conflicts of interest., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
5. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
- Author
-
Hepp P, Fasching PA, Beckmann MW, Fehm T, Salmen J, Hagenbeck C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Kurt AG, Friedl TWP, Janni W, and Rack B
- Subjects
- Adult, Aged, Antigens, Tumor-Associated, Carbohydrate blood, Biomarkers, Tumor blood, Breast Neoplasms blood, Chemotherapy, Adjuvant methods, Clinical Trials as Topic, Female, Humans, Middle Aged, Retrospective Studies, Young Adult, Antigens, Tumor-Associated, Carbohydrate drug effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Granulocyte Colony-Stimulating Factor administration & dosage, Neoplastic Cells, Circulating drug effects
- Abstract
Background: Little is known about the effect of granulocyte colony-stimulating factor (G-CSF) treatment during adjuvant chemotherapy on prognostic markers. The present study explored the association between G-CSF and changes in cancer antigen (CA)27.29 and circulating tumor cell (CTC) levels during therapy., Patients and Methods: A total of 3754 node-positive or high-risk node-negative early-stage breast cancer patients were treated within the SUCCESS-A trial (simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial). CA27.29 and CTCs were determined before the start and within 6 weeks after the end of chemotherapy., Results: Overall, 1324 of the 2646 patients (50.0%) available for analysis had ≥ 1 G-CSF applications during chemotherapy. G-CSF application was significantly associated with CA27.29 status before and after chemotherapy (χ
2 = 30.6, df = 3; P < .001), because 238 patients (18.0%) with G-CSF treatment but only 146 (11.0%) without G-CSF treatment switched from a negative CA27.29 status before to a positive CA27.29 status after chemotherapy. In addition, patients with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy compared with patients without any G-CSF application during chemotherapy (Mann-Whitney U test; Z = -7.81, P < .001). No significant association was found between G-CSF application and CTC status before or after chemotherapy (χ2 = 1.2, df = 3; P = .75)., Conclusion: Cautious interpretation is needed regarding elevated levels of MUC-1-derived tumor markers such as CA27.29 shortly after adjuvant chemotherapy when G-CSF has been given, because G-CSF treatment was associated with increased CA27.29 levels after chemotherapy., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
6. Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells.
- Author
-
Kutuk O, Aytan N, Karakas B, Kurt AG, Acikbas U, Temel SG, and Basaga H
- Subjects
- Antineoplastic Agents pharmacology, Cisplatin pharmacology, Colonic Neoplasms, HCT116 Cells, Humans, Lysosomes drug effects, Lysosomes metabolism, Membrane Potentials drug effects, Mitochondrial Proteins, Apoptosis, Apoptosis Regulatory Proteins metabolism, DNA Damage, Membrane Proteins metabolism, Reactive Oxygen Species metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
Necrosis, apoptosis and autophagic cell death are the main cell death pathways in multicellular organisms, all with distinct and overlapping cellular and biochemical features. DNA damage may trigger different types of cell death in cancer cells but the molecular events governing the mode of cell death remain elusive. Here we showed that increased BH3-only protein BIK levels promoted cisplatin- and UV-induced mitochondrial apoptosis and biphasic ROS production in HCT-116 wild-type cells. Nonetheless, early single peak of ROS formation along with lysosomal membrane permeabilization and cathepsin activation regulated cisplatin- and UV-induced necrosis in p53-null HCT-116 cells. Of note, necrotic cell death in p53-null HCT-116 cells did not depend on BIK, mitochondrial outer membrane permeabilization or caspase activation. These data demonstrate how cancer cells with different p53 background respond to DNA-damaging agents by integrating distinct cell signaling pathways dictating the mode of cell death.
- Published
- 2017
- Full Text
- View/download PDF
7. Production of methionine γ- lyase in recombinant Citrobacter freundii bearing the hemoglobin gene.
- Author
-
Kahraman H, Aytan E, and Kurt AG
- Subjects
- Carbon metabolism, Carbon-Sulfur Lyases genetics, Fermentation, Bacterial Proteins genetics, Carbon-Sulfur Lyases biosynthesis, Citrobacter freundii enzymology, Citrobacter freundii genetics, Recombinant Proteins biosynthesis, Recombinant Proteins genetics, Truncated Hemoglobins genetics
- Abstract
The production of antileukemic enzyme methionine γ-lyase (MGL) in distinctly related bacteria, Citrobacter freundii and in their recombinants expressing the Vitresocilla hemoglobin (VHb) has been studied. This study concerns the potential of Citrobacter freundii expressing the Vitreoscilla hemoglobin gene (vgb) for the methionine γ- liyase production. Methionine γ- liyase production by Citrobacter freundii and its vgb(-) and vgb(+) bearing recombinant strain was studied in shake-flasks under 200 rpm agitation, culture medium and 30 °C in a time-course manner. The vgb(+) and especially the carbon type had a dramatic effect on methionine γ- liyase production. The vgb(+) strain of C. freundii had about 2-fold and 3.1-fold higher levels of MGL than the host and vgb(-) strain, respectively.
- Published
- 2011
- Full Text
- View/download PDF
8. Production of L-DOPA and dopamine in recombinant bacteria bearing the Vitreoscilla hemoglobin gene.
- Author
-
Kurt AG, Aytan E, Ozer U, Ates B, and Geckil H
- Subjects
- Bacterial Proteins genetics, Citrobacter freundii genetics, Citrobacter freundii metabolism, Dopamine genetics, Erwinia genetics, Erwinia metabolism, Hemeproteins genetics, Levodopa genetics, Recombinant Proteins genetics, Truncated Hemoglobins genetics, Tyrosine metabolism, Tyrosine Phenol-Lyase metabolism, Bacterial Proteins metabolism, Dopamine biosynthesis, Hemeproteins metabolism, Levodopa biosynthesis, Recombinant Proteins biosynthesis, Truncated Hemoglobins metabolism
- Abstract
Given the well-established beneficial effects of Vitreoscilla hemoglobin (VHb) on heterologous organisms, the potential of this protein for the production of L-DOPA and dopamine in two bacteria, Citrobacter freundii and Erwinia herbicola, was investigated. The constructed recombinants bearing the VHb gene (vgb(+)) had substantially higher levels of cytoplasmic L-DOPA (112 mg/L for C. freundii and 97 mg/L for E. herbicola) than their respective hosts (30.4 and 33.8 mg/L) and the vgb(-) control strains (35.6 and 35.8 mg/L). Further, the vgb(+) recombinants of C. freundii and E. herbicola had 20-fold and about two orders of magnitude higher dopamine levels than their hosts, repectively. The activity of tyrosine phenol-lyase, the enzyme converting L-tyrosine to L-DOPA, was well-correlated to cytoplasmic L-DOPA levels. As cultures aged, higher tyrosine phenol-lyase activity of the vgb(+) strains was more apparent.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.